We serve Chemical Name:5,6-dibromohex-1-ene CAS:4285-48-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:5,6-dibromohex-1-ene
CAS.NO:4285-48-7
Synonyms:5,6-dibromo-hex-1-ene;1,2-DIBROMO-5-HEXENE;1-Hexene,5,6-dibromo;5,6-Dibromo-1-hexene
Molecular Formula:C6H10Br2
Molecular Weight:241.95200
HS Code:2903399090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:228.8ºC at 760mmHg
Density:1.619 g/cm3
Index of Refraction:1.514
PSA:
Exact Mass:239.91500
LogP:3.11100
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 5,6-dibromo-hex-1-ene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5,6-Dibromo-1-hexene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5,6-dibromo-hex-1-ene Use and application,5,6-Dibromo-1-hexene technical grade,usp/ep/jp grade.
Related News: MSD – known as Merck in the US and Canada – is jointly developing Verquvo with Bayer. While MSD hold the commercial rights to the heart failure med in the US, Bayer has the exclusive commercial rights in the rest of the world. trans-[Pt(C6H4Me-p)Cl(PEt3)(P(OPh)3)] manufacturers A multitude of enzymes is now utilized for generating active pharmaceutical ingredients (APIs) and intermediates for their production, with such reagents offering numerous advantages compared to using traditional metal catalysts. 1,3,4,5,6-penta-O-acetyl-myo-inositol 2-[[(4,4′-dimethoxytrityl)biotinyl-6-aminohexyl](β-cyanoethyl)phosphate] suppliers MSD – known as Merck in the US and Canada – is jointly developing Verquvo with Bayer. While MSD hold the commercial rights to the heart failure med in the US, Bayer has the exclusive commercial rights in the rest of the world. 4-Amino-2-hydroxy-benzoic acid [(10S,13S,17S)-17-ethyl-17-hydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-(3E)-ylidene]-hydrazide vendor & factory The CHMP has agreed on an update of recommendations for monitoring patients. Healthcare professionals should now check their patients for signs of blood cancers at least once a year for 15 years.1,As the Covid-19 pandemic continues to challenge the global drug supply chain, nations are looking for new ways to enable native producers to continue scaling up. Now, an Israeli API maker is dropping a down payment into an Indian intermediates company to ramp up its own manufacturing base.
